Download PDF
Exp Clin Endocrinol Diabetes 2012; 120(03): 169-170
DOI: 10.1055/s-0031-1301290
Short Communication
© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

Serum Procalcitonin and Calcitonin Normal Values Before and After Calcium Gluconate Infusion

L. Giovanella
1   Department of Nuclear Medicine and Thyroid Centre, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
2   Department of Clinical Chemistry and Laboratory Medicine, Ente Ospedaliero Cantonale, Bellinzona, Switzerland
› Author Affiliations
Further Information

Publication History

received 21 July 2011
first decision 23 December 2011

accepted 04 January 2012

Publication Date:
10 February 2012 (online)

Also available at
    Permissions and Reprints

Abstract

Aim:

To evaluate and compare serum procalcitonin (PCT) and calcitonin (hCT) levels before and after stimulation with intravenous calcium gluconate in selected thyroid healthy subjects.

Methods:

There were enrolled 78 healthy blood donors with no history of thyroid disease, renal disease, neuroendocrine tumours, infections or inflammatory diseases, and taking no proton-pump inhibitors medication. Serum PCT and hCT were measured before and after intravenous injection of 2.5 mg/kg calcium gluconate.

Results:

Undetectable basal PCT values were found in all subjects while a marginal increase occurred only in 2 male subjects after stimulation. The basal and stimulated 95th percentile hCT values were 7.80 pg/mL and 102 pg/mL in males and 5.20 pg/mL and 78.5 pg/mL in females, respectively.

Conclusions:

Our data suggest that calcium gluconate physiologically stimulate the release of mature hCT molecule from the parafollicular C-cells with no or minimal effects on the PCT release. Our preliminary results form a reliable reference platform for basal and calcium-stimulated PCT measurements in clinical studies.

Key words

calcitonin - procalcitonin - medullary thyroid carcinoma - calcium gluconate
 

  • References

  • 1 Algeciras-Schimnich A, Preissenr CM, Theobald P et al. Procalcitonin: a marker for the diagnosis and follow-up of patients with medullary thyroid carcinoma. J Clin Endocrinol Metab 2009; 94: 861-868
    PubMedGoogle Scholar
  • 2 Barbot N, Calmettes C, Schuffenecker I et al. Pentagastrin stimulation test and early diagnosis of medullary thyroid carcinoma using an immunoradiometric assay of calcitonin: comparison with genetic screening in hereditary medullary thyroid carcinoma. J Clin Endocrinol Metab 1994; 78: 114-120
    CrossrefPubMedGoogle Scholar
  • 3 Doyle P, Dueren C, Nerlich K et al. Potency and tolerance of calcitonin stimulation with high-dose calcium versus pentagastrin in normal adults. J Clin Endocrinol Metab 2009; 94: 2970-2974
    CrossrefPubMedGoogle Scholar
  • 4 Giovanella L, Maffioli M, Suriano S et al. Elevated calcitonin and procalcitonin levels in nonmedullary benign and malignant thyroid nodules. Clin Endocrinol 2010; 72: 852-853
    PubMedGoogle Scholar
  • 5 Karges W, Dralle HH, Raue F et al. German Society for Endocrinology (DGE): Thyroid Section. Calcitonin measurement to detect medullary thyroid carcinoma in nodular goiter: German evidence-based consensus recommendation. Exp Clin Endocrinol Diabetes 2004; 112: 52-58
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Kratzsch J, Petzold A, Raue F et al. Basal and stimulated calcitonin and procalcitonin in various assays in patients with and without medullary thyroid cancer. Clin Chem 2011; 57: 467-474
    CrossrefPubMedGoogle Scholar
  • 7 Steinbach G, Rau B, Debard AL et al. Multicenter evaluation of a new immunoassay for procalcitonin measurement on the Kryptor® System. Clin Chem Lab Med 2004; 42: 440-449
    CrossrefPubMedGoogle Scholar